Novartis AG

Alpha Score of 47 reflects weak overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Novartis AG Sponsored ADR represents the American Depositary Receipts of Novartis AG, a Swiss-based innovative medicines company headquartered in Basel. This ADR enables U.S. investors convenient access to Novartis AG shares, facilitating liquidity and exposure to global pharmaceutical innovation. Novartis AG focuses on researching, developing, producing, distributing, and commercializing advanced treatments across key therapeutic areas, including oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and respiratory conditions. Its portfolio features prominent products such as Entresto and Leqvio in cardiovascular; Cosentyx, Xolair, and Ilaris in immunology; Kesimpta, Zolgensma, and Mayzent in neuroscience; and oncology offerings like Kisqali, Pluvicto, Lutathera, Kymriah, and Scemblix. Additionally, established brands like Lucentis and Sandostatin support ongoing patient care. Operating as a single global segment post its generics spin-off, Novartis AG delivers medicines worldwide, emphasizing research-driven solutions that address serious diseases and enhance healthcare accessibility. Founded in 1996, the company maintains a significant presence in the healthcare sector through its broad therapeutic expertise.